Last reviewed · How we verify
ISV-303
ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.
ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway. Used for Cancer (specific indication under clinical evaluation in Phase 3).
At a glance
| Generic name | ISV-303 |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for ISV-303 remain proprietary, Sun Pharmaceutical's development of this Phase 3 candidate suggests it targets immune checkpoint regulation to overcome tumor-mediated immune suppression. The drug is intended to restore T-cell function and promote anti-tumor immunity in cancer patients.
Approved indications
- Cancer (specific indication under clinical evaluation in Phase 3)
Common side effects
Key clinical trials
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISV-303 CI brief — competitive landscape report
- ISV-303 updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI